FrancophonIA/ELRC3.0 huggingface dataset:
English: At baseline 79% of 219 patients enrolled and treated in the study were taking methotrexate (mean dose at study entry, 12.3 mg/m2/week) and 21% of patients received abatacept monotherapy.
Slovenian: V izhodišču je 79 % od 219 bolnikov, ki so bili vključeni in zdravljeni v študiji, jemalo metotreksat (srednji odmerek ob vstopu v študijo 12,3 mg/m2/teden), 21 % bolnikov pa se je zdravilo z abataceptom v monoterapiji.
English: During the 24-month cumulative period of the pJIA SC study (4-month short term period plus 20-month extension period), a higher frequency of infections was reported in the 2 to 5 year age cohort (87.0%) compared to that reported in the 6 to 17 year age cohort (68.2%).
Slovenian: Med 24-mesečnim kumulativnim obdobjem v študiji s.c. uporabe pri pJIA (4-mesečno kratkoročno obdobje in 20-mesečno podaljšano obdobje) so poročali o večji pogostnosti okužb v kohorti bolnikov, starih od 2 do 5 let (87,0 %), v primerjavi s kohorto bolnikov, starih od 6 do 17 let (68,2 %).
English: Response rates at the end of Period A, at the end of Period B and after 5 years exposure in Period C are summarized in Table 9:
Slovenian: Deleži odziva ob koncu obdobja A, ob koncu obdobja B in po 5 letih zdravljenja v obdobju C so povzeti v preglednici 9:
English: Very common (may affect more than 1 in 10 people): infections of the upper airway (including infections of the nose, throat and sinuses).
Slovenian: Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov): okužbe zgornjih dihal (vključno z okužbami nosu, žrela in sinusov).
English: Response rates at the end of Period A, at the end of Period B and after 5 years exposure in Period C are summarized in Table 10:
Slovenian: Deleži odziva ob koncu obdobja A, ob koncu obdobja B in po 5 letih zdravljenja v obdobju C so povzeti v preglednici 10:
English: ORENCIA can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate.
Slovenian: Zdravilo ORENCIA se lahko uporablja v monoterapiji v primeru intolerance za metotreksat, ali če zdravljenje z metotreksatom ni primerno.
English: If any serious allergic or anaphylactic reaction occurs, intravenous or subcutaneous ORENCIA therapy should be discontinued immediately and appropriate therapy initiated, and the use of ORENCIA should be permanently discontinued.
Slovenian: V primeru pojava kakršne koli resne alergijske ali anafilaksijske reakcije je treba zdravljenje z zdravilom ORENCIA v obliki intravenske infuzije ali subkutane injekcije nemudoma prekiniti in uvesti ustrezno zdravljenje.
English: During the 12-week pre-filled pen period of the substudy, there were no deaths or related SAEs.
Slovenian: Med 12-tedenskim obdobjem podštudije uporabe napolnjenega injekcijskega peresnika niso poročali o smrtnih primerih ali resnih neželenih učinkih.
English: Remove the flip-top from the vial and wipe the top with an alcohol swab.
Slovenian: Z vrha viale odstranite dvižno zaporko in vrh obrišite z alkoholnim tamponom.
English: MRI Synovitis Score
Slovenian: MRI ocena sinovitisa
English: If a single intravenous dose is given to start the treatment, the first subcutaneous injection of ORENCIA should be given within a day of the intravenous infusion, followed by the weekly 125 mg subcutaneous injections.
Slovenian: Če bo zdravnik zdravljenje uvedel z enkratnim intravenskim odmerkom, boste prvo podkožno injekcijo zdravila ORENCIA prejeli še isti dan kot intravensko infuzijo, nato pa boste podkožne injekcije v odmerku 125 mg prejemali enkrat na teden.
English: Before you use the ClickJect Pen for the first time, make sure your healthcare provider shows you the right way to use it.
Slovenian: Poskrbite, da vam pred prvo uporabo ClickJect injekcijskega peresnika zdravstveni delavec pokaže njegovo pravilno uporabo.
English: In the 2 to 5 year age cohort, the overall rate of seropositivity during the cumulative period including post abatacept follow-up was 15.2% (7/46): 10.9% (5/46) on treatment and 37.5% (3/8) after discontinuation of abatacept (≥ 28 days after the last dose).
Slovenian: V kohorti bolnikov, starih od 2 do 5 let, je celokupen delež seropozitivnosti v kumulativnem obdobju, vključno z obdobjem spremljanja po uporabi abatacepta, znašal 15,2 % (7/46): 10,9 % (5/46) med zdravljenjem in 37,5 % (3/8) po ukinitvi zdravljenja z abataceptom (≥ 28 dni po uporabi zadnjega odmerka).
English: In a pre- and postnatal development study in rats, limited changes in immune function were observed at 11-fold higher than a human 10 mg/kg dose based on AUC (see section 5.3).
Slovenian: Pri študijah prenatalnega in postnatalnega razvoja pri podganah so pri odmerkih, ki so bili na osnovi AUC 11-krat večji od odmerka 10 mg/kg pri človeku, opazili manjše spremembe imunske funkcije (glejte poglavje 5.3).
English: † p < 0.05, abatacept plus MTX vs MTX plus placebo a Fixed dose approximating 10 mg/kg (see section 4.2).
Slovenian: † p < 0,05, abatacept in MTX v primerjavi z MTX in placebom a Fiksni odmerek približno 10 mg/kg (glejte poglavje 4.2).
English: During the 24-week placebo-controlled period in the larger study PsA-II, the proportion of patients with adverse reactions was similar in the abatacept and placebo treatment groups (15.5% and 11.4%, respectively).
Slovenian: Med 24-tedenskim, s placebom nadzorovanim obdobjem, je bil v večji študiji PsA-II delež bolnikov z neželenimi učinki v skupini, ki je prejemala abatacept, podoben kot v skupini, ki je prejemala placebo (15,5% oziroma 11,4%).
English: There is limited experience with the use of abatacept in combination with TNF-inhibitors (see section 5.1).
Slovenian: Izkušenj z uporabo abatacepta v kombinaciji z zaviralci TNF je malo (glejte poglavje 5.1).
English: Needle guard (extended over needle)
Slovenian: Varovalo za iglo (sega preko igle)
English: Hypertension, blood pressure increased Uncommon Hypotension, hot flush, flushing, vasculitis, blood pressure decreased
Slovenian: Žilne bolezni pogosti hipertenzija, zvišanje krvnega tlaka občasni hipotenzija, navali vročine, vročinski oblivi, vaskulitis, znižanje krvnega tlaka
English: Over the 2 year study period, 3.8 % (12/318) and 1.5 % (5/328) patients treated with abatacept SC and adalimumab SC respectively reported autoimmune disorders mild to moderate in severity (e.g., psoriasis, Raynaud's phenomenon, erythema nodosum).
Slovenian: V 2-letnem obdobju študije so pri 3,8 % (12/318) bolnikov, ki so se zdravili z abataceptom s.c., in 1,5 % (5/328) bolnikov, ki so se zdravili z adalimumabom s.c., poročali o avtoimunskih boleznih blage do zmerne jakosti (npr. psoriaza, Raynaudov fenomen, nodozni eritem).
English: Twenty-two of 48 evaluable patients showed significant neutralizing activity.
Slovenian: Pomembna nevtralizirajoča aktivnost je bila ugotovljena pri 22 od 48 preiskanih bolnikov.
English: Clinical efficacy and safety in adult rheumatoid arthritis
Slovenian: Klinična učinkovitost in varnost pri odraslih z revmatoidnim artritisom
English: The progression of structural damage was lower in patients receiving continuous abatacept plus methotrexate treatment (for 24 months) compared to patients who initially received methotrexate plus placebo (for 12 months) and were switched to abatacept plus methotrexate for the next 12 months.
Slovenian: Pri bolnikih, ki so kontinuirano prejemali abatacept in metotreksat (24 mesecev) je bila progresija strukturnih poškodb manjša kot pri bolnikih, ki so v začetku prejemali metotreksat in placebo (12 mesecev) in so nato za naslednjih 12 mesecev prešli na zdravljenje z abataceptom in metotreksatom.
English: Patients entered in the trial were a mean 10.6 years of age with mean disease duration of 2.4 years.
Slovenian: Bolniki, ki so bili vključeni v preskušanje, so bili v povprečju stari 10,6 let, bolezen pa je v povprečju trajala 2,4 leta.
English: In rats and rabbits, abatacept exposure was up to 29-fold a human 10 mg/kg exposure based on AUC.
Slovenian: Pri podganah in kuncih je bila izpostavljenost abataceptu na osnovi AUC do 29-krat večja od izpostavljenosti človeka pri odmerku 10 mg/kg.
English: Patients were randomised to receive placebo or abatacept 3 mg/kg, 10 mg/kg, or two doses of 30 mg/kg followed by 10 mg/kg, without escape for 24 weeks, followed by open label abatacept 10 mg/kg monthly intravenous every month.
Slovenian: Bolniki so bili randomizirani tako, da so prejeli placebo ali abatacept v odmerku 3 mg/kg, 10 mg/kg, ali dva odmerka po 30 mg/kg.Sledilo je prejemanje odmerka 10 mg/kg brez izključitve za 24 tednov, nato pa odprto zdravljenje z abataceptom v odmerku 10 mg/kg mesečno intravensko vsak mesec.
English: While TNF-inhibitors did not influence abatacept clearance, in placebo-controlled clinical trials, patients receiving concomitant treatment with abatacept and TNF-inhibitors experienced more infections and serious infections than patients treated with only TNF-inhibitors.
Slovenian: Zaviralci TNF sicer niso vplivali na očistek abatacepta, vendar pa je bilo v s placebom nadzorovanih kliničnih preskušanjih število okužb in hudih okužb večje pri bolnikih, ki so se sočasno zdravili z abataceptom in zaviralci TNF, kot pri bolnikih, ki so se zdravili samo z zaviralci TNF.
English: In addition, inflammation of the thyroid and pancreas was frequently seen in both juvenile and adult rats exposed to abatacept.
Slovenian: Poleg tega so tako pri mladičih kot odraslih podganah, ki so bile izpostavljene abataceptu, pogosto opažali vnetja ščitnice in trebušne slinavke.
English: Improvement in physical function in controlled trials Methotrexate-Naive Inadequate response to Methotrexate
Slovenian: Izboljšanje fizične funkcije v nadzorovanih kliničnih preskušanjih Brez predhodnega zdravljenja z metotreksatom
English: Liver function test abnormal (including transaminases increased)
Slovenian: Bolezni jeter, žolčnika in žolčevodov pogosti nenormalni izvidi testov jetrne funkcije (vključno z zvišanjem transaminaz)
English: Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C - 8°C.
Slovenian: Dokazano je bilo, da je zdravilo kemično in fizikalno stabilno 24 ur, če se ga shranjuje pri temperaturi od 2°C - 8°C.
English: Population pharmacokinetic analysis of abatacept serum concentration data from patients with pJIA 6 to 17 years of age following administration of intravenous abatacept 10 mg/kg revealed that the estimated clearance of abatacept, when normalised for baseline body weight, was higher in pJIA patients (0.4 mL/h/kg for a child weighing 40 kg) versus adult rheumatoid arthritis patients.
Slovenian: Na osnovi podatkov o serumski koncentraciji abatacepta pri bolnikih s pJIA, starih od 6 do 17 let, po intravenski aplikaciji abatacepta v odmerku 10 mg/kg, je analiza populacijske farmakokinetike pokazala, da je vrednost ocenjenega očistka abatacepta, po normalizaciji na izhodiščno telesno maso, pri bolnikih s pJIA večja (0,4 ml/uro/kg za otroke s telesno maso 40 kg) kot pri odraslih bolnikih z revmatoidnim artritisom.
English: This medicinal product contains 0.014 mmol sodium (0.322 mg) per pre-filled pen, that is to say essentially ‘sodium- free'.
Slovenian: To zdravilo vsebuje 0,014 mmol natrija (0,322 mg) na napolnjen injekcijski peresnik, kar v bistvu pomeni “brez natrija”.
English: The absence of concomitant methotrexate (MTX) did not appear to be associated with a higher rate of seropositivity in Period B placebo recipients.
Slovenian: Kaže, da odsotnost sočasnega zdravljenja z metotreksatom (MTX) pri bolnikih, ki so v obdobju B študije prejemali placebo, ni bila povezana z večjim deležem seropozitivnosti.
English: Abatacept is not recommended for use in combination with TNF-inhibitors.
Slovenian: Uporabe abatacepta v kombinaciji z zaviralci TNF ne priporočamo.
English: - Remove the flip-top from the vial and wipe the top with an alcohol swab.
Slovenian: - Z vrha viale odstranite dvižno zaporko in vrh obrišite z alkoholnim tamponom.
English: Remove Needle Cover
Slovenian: Odstranite pokrovček igle
English: In SC-II, serious infections were reported in 3.8 % (12/318) of patients treated with abatacept SC weekly, none of which led to discontinuation and in 5.8 % (19/328) of patients treated with adalimumab SC every-other-week, leading to 9 discontinuations in the 24-month period.
Slovenian: V študiji SC-II so o resnih okužbah poročali pri 3,8 % (12/318) bolnikov, ki so se zdravili z abataceptom s.c. tedensko, vendar pa zdravljenja zaradi resne okužbe ni bilo treba prekiniti pri nobenem od teh bolnikov, in pri 5,8 % (19/328) bolnikov, ki so se zdravili z adalimumabom s.c. vsak drugi teden, zdravljenje pa je bilo v 24-mesečnem obdobju treba prekiniti pri 9 bolnikih z resno okužbo.
English: In study VI, the mean change in TSS at 12 months was significantly lower in patients treated with abatacept plus methotrexate compared to those treated with methotrexate plus placebo.
Slovenian: V študiji VI je bila povprečna sprememba vrednosti TSS po 12 mesecih signifikantno manjša pri bolnikih, ki so se zdravili z abataceptom in metotreksatom, kot pri bolnikih, ki so prejemali metotreksat in placebo.
English: By finding the right treatment plan for you, you may be able to slow down this disease process, which may help reduce long-term joint damage, as well as pain and fatigue and improve your overall quality of life.
Slovenian: To pomeni, da lahko kljub zdravljenju pride do poškodb sklepov, simptomi pa so pri tem lahko prisotni ali pa tudi ne. S pravilnim zdravljenjem se bolezenski proces lahko upočasni, preprečijo dolgoročne poškodbe sklepov, olajša bolečina in utrujenost ter izboljša splošna kakovost življenja.
English: Comprehensive instructions for the preparation and administration of ORENCIA in a pre-filled syringe are given in the package leaflet and “Important instructions for use”.
Slovenian: Podrobna navodila za pripravo in dajanje zdravila ORENCIA v napolnjeni injekcijski brizgi so navedena v navodilu za uporabo in “Pomembnih navodilih za uporabo”.
English: The incidence rate of autoimmune disorders in abatacept-treated patients during the double-blind period was 8.8 (7.6, 10.1) per 100 person-years of exposure and for placebo-treated patients was 9.6 (7.9, 11.5) per 100 person-years of exposure.
Slovenian: Stopnja pojavnosti avtoimunskih bolezni je pri bolnikih, ki so med dvojno slepim obdobjem prejemali abatacept, znašala 8,8 (7,6; 10,1) na 100 bolnik-let izpostavljenosti, pri bolnikih, ki so prejemali placebo pa 9,6 (7,9; 11,5) na 100 bolnik-let izpostavljenosti.
English: Do not give the injection in any areas with scars or stretch marks.
Slovenian: Ne injicirajte v predele z brazgotinami ali s strijami.
English: Listed in Table 1 are adverse reactions observed in clinical trials and post-marketing experience presented by system organ class and frequency, using the following categories: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000).
Slovenian: V preglednici 1 so neželeni učinki, opaženi v kliničnih preskušanjih in med spremljanjem zdravila po prihodu na trg, navedeni glede na organski sistem in pogostnosti, pri čemer so uporabljene naslednje kategorije: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000).
English: No significant changes in PASI scores with abatacept treatment were seen over the 24-week doubleblind period.
Slovenian: V 24-tedenskem dvojno slepem obdobju pomembnih sprememb v oceni PASI pri zdravljenju z abataceptom niso opazili.
English: Upon reinitiating therapy, there were no injection reactions and no other safety concerns in patients who were withdrawn from subcutaneous therapy for up to 3 months relative to those who remained on subcutaneous therapy, whether therapy was reintroduced with or without an intravenous loading dose.
Slovenian: V primerjavi z bolniki, ki so se kontinuirano zdravili subkutano, pri bolnikih, pri katerih je bilo subkutano zdravljenje prekinjeno za največ 3 mesece, po ponovni uvedbi zdravljenja niso poročali o reakcijah na injiciranje ali o drugih težavah z varnostjo, in sicer ne glede na to, ali je bilo zdravljenje ponovno uvedeno z začetnim intravenskim odmerkom ali brez njega.
English: the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor.
Slovenian: zdravljenje zmernega do hudega aktivnega revmatoidnega artritisa (RA) pri odraslih bolnikih z nezadostnim odzivom na predhodno zdravljenje z enim ali več zdravili iz skupine imunomodulirajočih protirevmatičnih zdravil (DMARDs - disease-modifying anti-rheumatic drugs), vključno z metotreksatom (MTX) ali zaviralcem tumorje nekrotizirajočega faktorja-alfa
English: Patients were allowed to receive stable doses of concomitant methotrexate, low dose corticosteroids (equivalent to ≤ 10 mg of prednisone) and/or NSAIDs during the trial.
Slovenian: Bolniki so med preskušanjem lahko sočasno prejemali stabilne odmerke metotreksata, nizke odmerke kortikosteroidov (v odmerkih, enakovrednih ≤ 10 mg prednizona) in/ali nesteroidna protivnetna zdravila (NSAID).
English: Listed in Table 2 are adverse reactions observed in clinical trials and post-marketing experience presented by system organ class and frequency, using the following categories: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000).
Slovenian: V preglednici 2 so neželeni učinki, opaženi v kliničnih preskušanjih in med spremljanjem zdravila po prihodu na trg, navedeni glede na organski sistem in pogostnosti, pri čemer so uporabljene naslednje kategorije: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000).
English: C. Check the liquid in the syringe Hold the syringe by its body, with the covered needle pointing down.
Slovenian: C. Preverite tekočino v napolnjeni injekcijski brizgi Injekcijsko brizgo primite za telo tako, da je pokrita igla usmerjena navzdol.
English: One mL pre-filled syringe (Type 1 glass) in a pre-filled pen.
Slovenian: 1 ml napolnjena injekcijska brizga (steklo tipa 1) v napolnjenem injekcijskem peresniku.
English: The safety and efficacy of ORENCIA solution for injection in pre-filled pen for subcutaneous administration in children below 18 years of age have not been established.
Slovenian: Varnost in učinkovitost zdravila ORENCIA raztopina za injiciranje v napolnjenem injekcijskem peresniku za subkutano uporabo pri otrocih, mlajših od 18 let, nista bili dokazani.
English: Antibodies directed against the whole abatacept molecule or to the CTLA-4 portion of abatacept were assessed by an ECL assay in patients with pJIA following repeated treatment with subcutaneous abatacept.
Slovenian: Protitelesa proti celotni molekuli abatacepta ali CTLA-4 delu abatacepta so ovrednotili z ECL testi pri bolnikih s pJIA po ponavljajočem se subkutanem zdravljenju z abataceptom.
English: Patients in the sub-study (n=117) of the open-label extension of study SC-I received 125 mg of subcutaneous abatacept administered weekly via the pre-filled syringe for at least 4 months, and were then switched to receive 125 mg SC abatacept administered weekly via the pre-filled pen for 12 weeks.
Slovenian: Bolniki v podštudiji (n=117) odprtega podaljška študije SC-I so najmanj 4 mesece enkrat na teden prejemali 125 mg abatacepta subkutano v napolnjeni injekcijski brizgi, nato pa so za 12 tednov prešli na uporabo 125 mg abatacepta s.c. enkrat na teden v napolnjenem injekcijskem peresniku.
English: In the placebo-controlled clinical trials with abatacept, infections at least possibly related to treatment were reported in 22.7% of abatacept-treated patients and 20.5% of placebo-treated patients.
Slovenian: V s placebom nadzorovanih kliničnih preskušanjih, izvedenih z abataceptom, so o okužbah, ki bi lahko bile povezane z zdravljenjem, poročali pri 22,7% bolnikov, ki so prejemali abatacept, in 20,5% bolnikov, ki so prejemali placebo.
English: Study II, III, IV, and VI patients were randomised to receive a fixed dose approximating 10 mg/kg of abatacept or placebo for 12 (studies II, IV, and VI) or 6 months (study III).
Slovenian: V študijah II, III, IV in VI so bili bolniki randomizirani tako, da so 12 mesecev (študije II, IV in VI) ali 6 mesecev (študija III) prejemali fiksni odmerek približno 10 mg/kg abatacepta ali placeba.
English: The safety and efficacy of abatacept in the ongoing SC study were consistent with the results seen with abatacept in the IV study (see section 5.1 of the ORENCIA solution for injection in pre-filled syringe SmPC for complete study description and results).
Slovenian: Varnost in učinkovitost abatacepta v študiji subkutane uporabe, ki še poteka, je konsistentna z rezultati študije intravenske uporabe abatacepta (za popoln opis študije in rezultate glejte poglavje 5.1 povzetka glavnih značilnosti zdravila ORENCIA raztopina za injiciranje v napolnjeni injekcijski brizgi).
English: Record the date, time and site where you injected.
Slovenian: Zabeležite datum, čas in mesto injiciranja.
English: Examine the ClickJect Pre-filled Pen:
Slovenian: Preverite ClickJect napolnjen injekcijski peresnik:
English: The dose of abatacept was 500 mg for patients weighing less than 60 kg, 750 mg for patients weighing 60 to 100 kg, and 1,000 mg for patients weighing greater than 100 kg.
Slovenian: Pri bolnikih s telesno maso, manjšo od 60 kg, je bil odmerek abatacepta 500 mg, pri bolnikih s telesno maso od 60 do 100 kg 750 mg, pri bolnikih s telesno maso, večjo od 100 kg, pa 1.000 mg.
English: The COPD patients treated with abatacept developed adverse reactions more frequently than those treated with placebo (51.4% vs. 47.1%, respectively).
Slovenian: Pri bolnikih s KOPB, ki so prejemali abatacept, so bili neželeni učinki pogostejši kot pri bolnikih, ki so prejemali placebo (51,4% v primerjavi s 47,1%).
English: Structural and inflammatory MRI assessment in study SC-III Mean Treatment Difference between Abatacept SC+MTX vs. MTX at 12 Months (95% CI)* MRI Erosion Score
Slovenian: MRI ocena strukturnih in vnetnih sprememb v študiji SC-III Povprečna razlika zdravljenja med abatacept s.c.+MTX v primerjavi z MTX v 12. mesecu (95 % IZ)*
English: Before you use ORENCIA, your doctor may examine you for hepatitis.
Slovenian: Preden boste začeli uporabljati zdravilo ORENCIA vas bo zdravnik morda pregledal na hepatitis.
English: What you need to know before you use ORENCIA 3.
Slovenian: Kaj morate vedeti, preden boste uporabili zdravilo ORENCIA 3.
English: B. Prepare your injection site Wipe your injection site with an alcohol swab in a circular motion.
Slovenian: B. Priprava mesta za injiciranje S krožnim gibom obrišite mesto injiciranja z alkoholnim zložencem.
English: Acute infusion-related events (adverse reactions occurring within 1 hour of the start of the infusion) in seven pooled intravenous studies (for studies II, III, IV and V see section 5.1) were more common in the abatacept-treated patients than the placebo-treated patients (5.2% for abatacept, 3.7% for placebo).
Slovenian: V sedmih združenih študijah intravenske uporabe (študije II, III, IV in V, glejte poglavje 5.1) so bili akutni učinki, povezani z infundiranjem (neželeni učinki, ki so se pojavili v 1 uri po začetku infundiranja), pogostejši pri bolnikih, ki so prejemali abatacept, kot pri bolnikih, ki so prejemali placebo (5,2% za abatacept, 3,7% za placebo).
English: What ORENCIA looks like and contents of the pack ORENCIA solution for injection (injection) is a clear, colourless to pale yellow solution.
Slovenian: Izgled zdravila ORENCIA in vsebina pakiranja ORENCIA raztopina za injiciranja (injekcija) je bistra, brezbarvna do bledo rumena raztopina.
English: Therefore, concurrent therapy with abatacept and a TNF-inhibitor is not recommended.
Slovenian: Sočasnega zdravljenja z abataceptom in zaviralcem TNF ne priporočamo.